You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

imids

Showing 1 - 25 of 77
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hematological Malignancy, Solid Tumor Trial (OT-A201, IMids, Bevacizumab)

Not yet recruiting
  • Hematological Malignancy
  • Solid Tumor
  • (no location specified)
Apr 24, 2023

ImmuNe-Mediated Inflammatory Diseases Trial in Milan (Questionnaires)

Not yet recruiting
  • ImmuNe-Mediated Inflammatory Diseases
  • Questionnaires
  • Milan, Italy
    IRCCS Istituto Ortopedico Galeazzi
Jan 10, 2022

Safety and Efficacy Trial in Suzhou (anti-CD19 and anti-BCMA CAR, Immunomodulatory drugs)

Recruiting
  • Safety and Efficacy
  • anti-CD19 and anti-BCMA CAR
  • Immunomodulatory drugs
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
May 17, 2021

Venous Thromboembolism Trial in Valencia (Apixaban 2.5 MG)

Terminated
  • Venous Thromboembolism
  • Apixaban 2.5 MG
  • Valencia, Spain
  • +3 more
Feb 12, 2021

Incident IMID in Patients Treated With Biologics and

Not yet recruiting
  • Inflammatory Disease
    • Paris, France
      Hôpital Saint-Antoine
    Jan 23, 2023

    NK/T Cell Lymphoma Nos Trial in Beijing (Sintilimab, Lenalidomide)

    Unknown status
    • NK/T Cell Lymphoma Nos
    • Beijing, China
      Beijing Tongren Hospital
    May 6, 2020

    Ustekinumab in Participants Suffering From Inflammatory Bowel

    Recruiting
    • Crohn Disease
    • Colitis, Ulcerative
    • Vandoeuvre les Nancy, France
      CHU de Nancy - Hôpital de Brabois
    Aug 17, 2022

    Chronic Inflammatory Disease, Angioedema, Severe Asthma Trial in Lille (Biobanking with genetic analysis, SF-12 questionnaire)

    Recruiting
    • Chronic Inflammatory Disease
    • +8 more
    • Biobanking with genetic analysis
    • SF-12 questionnaire
    • Lille, France
      Hop Claude Huriez Chu Lille
    May 17, 2022

    Thrombosis in Multiple Myeloma in an University Medical Center

    Recruiting
    • Multiple Myeloma
    • +2 more
    • Multiple myeloma
    • Groningen, Netherlands
      University Medical Center Groningen
    Sep 12, 2022

    Learn How Triple Class Refractory Multiple Myeloma Are Treated

    Not yet recruiting
    • Relapse Multiple Myeloma
    • Refractory Multiple Myeloma
      • (no location specified)
      Feb 15, 2023

      Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)

      Not yet recruiting
      • Relapsed/Refractory Multiple Myeloma
      • ISB 2001
      • Benowa, Queensland, Australia
        Pindara Private Hospital
      May 18, 2023

      Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS) Trial in Boston

      Active, not recruiting
      • Langerhans Cell Histiocytosis (LCH)
      • +2 more
      • Boston, Massachusetts
        Dana-Farber Cancer Institute
      Aug 26, 2022

      Relapsed/Refractory Multiple Myeloma Trial in Australia, United States (ISB 1442 SC injection escalating doses, ISB 1442 SC

      Not yet recruiting
      • Relapsed/Refractory Multiple Myeloma
      • ISB 1442 SC injection escalating doses
      • ISB 1442 SC injection at RP2D
      • New York, New York
      • +5 more
      Jun 17, 2022

      Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis Trial in Aarhus (Interdisciplinary management, Usual-care management)

      Recruiting
      • Psoriasis
      • +5 more
      • Interdisciplinary management
      • Usual-care management
      • Aarhus, Denmark
        National Center for Autoimmune Diseases, Aarhus University Hospi
      Mar 19, 2021

      Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial run by the

      Not yet recruiting
      • Multiple Myeloma
      • +2 more
      • 18F-fluciclovine injection
      • 18F-FDG PET/CT
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Oct 31, 2023

      MMRR Treated With Belantamab Mafotidine on Monotherapy

      Not yet recruiting
      • Multiple Myeloma
      • Belantamab mafodotin
      • (no location specified)
      May 23, 2022

      Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

      Not yet recruiting
      • Relapsed and Refractory Multiple Myeloma
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Sep 15, 2023

      MDS Trial in Beijing (Lenalidomide, Azacitidine)

      Not yet recruiting
      • Myelodysplastic Syndromes
      • Beijing, China
        Peking union medical college hospital
      Aug 16, 2023

      Main Hypothesis is That in the NASH Associated to IMIDs, to Different Phenotypes co Exist Trial in Santander

      Unknown status
      • Main Hypothesis is That in the NASH Associated to IMIDs, to Different Phenotypes co Exist
        • Santander, Cantabria, Spain
          Hospital Universitario Marques de Valdecilla
        Nov 29, 2018

        Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma Trial in Tianjin (Allogeneic Hematopoietic Stem Cell

        Unknown status
        • Multiple Myeloma
        • +8 more
        • Allogeneic Hematopoietic Stem Cell Transplantation
        • +5 more
        • Tianjin, Tianjin, China
          Institute of Hematology and Blood Diseases Hospital Chinese Acad
        Jul 3, 2019

        Multiple Myeloma Trial (RP followed by MPR)

        Active, not recruiting
        • Multiple Myeloma
        • RP followed by MPR
        • (no location specified)
        Mar 24, 2022

        Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

        Recruiting
        • Cutaneous T-Cell Lymphoma
        • +3 more
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 23, 2023

        Multiple Myeloma Trial in Worldwide (Iberdomide)

        Recruiting
        • Multiple Myeloma
        • Nantes, France
        • +3 more
        Aug 16, 2022

        Multiple Myeloma Trial in United States (Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone)

        Recruiting
        • Multiple Myeloma
        • Ruxolitinib Oral Tablet [Jakafi]
        • +2 more
        • Alhambra, California
        • +12 more
        Apr 18, 2022

        Relapsed/Refractory Multiple Myeloma Trial in France, United States (ISB 1342)

        Recruiting
        • Relapsed/Refractory Multiple Myeloma
        • ISB 1342
        • Little Rock, Arkansas
        • +21 more
        May 10, 2022